Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis

BACKGROUND: The present network meta-analysis was conducted to perform an indirect comparison among ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma (HCC) progressed on sorafenib treatment. METHODS: A systematic review through Medline, Embase, and Cochran...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui, Xie, Fangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462645/
https://www.ncbi.nlm.nih.gov/pubmed/34559096
http://dx.doi.org/10.1097/MD.0000000000027013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462645/
https://www.ncbi.nlm.nih.gov/pubmed/34559096
http://dx.doi.org/10.1097/MD.0000000000027013

Ejemplares similares